In utero origin of myelofibrosis presenting in adult monozygotic twins
Authors
Sousos, N.M, N. L.
Simoglou Karali, C.
Louka, E.
Bienz, N.
Royston, D.
Clark, S. A.
Hamblin, A.
Howard, K.
Mathews, V.
George, B.
Roy, A.
Psaila, B.
Wedge, David C
Mead, A. J.
Affiliation
Medical Research Council (MRC) Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, National Institute for Health Research Biomedical Research Centre, University of Oxford, Oxford, UKIssue Date
2022
Metadata
Show full item recordAbstract
The latency between acquisition of an initiating somatic driver mutation by a single-cell and clinical presentation with cancer is largely unknown. We describe a remarkable case of monozygotic twins presenting with CALR mutation-positive myeloproliferative neoplasms (MPNs) (aged 37 and 38 years), with a clinical phenotype of primary myelofibrosis. The CALR mutation was absent in T cells and dermal fibroblasts, confirming somatic acquisition. Whole-genome sequencing lineage tracing revealed a common clonal origin of the CALR-mutant MPN clone, which occurred in utero followed by twin-to-twin transplacental transmission and subsequent similar disease latency. Index sorting and single-colony genotyping revealed phenotypic hematopoietic stem cells (HSCs) as the likely MPN-propagating cell. Furthermore, neonatal blood spot analysis confirmed in utero origin of the JAK2V617F mutation in a patient presenting with polycythemia vera (aged 34 years). These findings provide a unique window into the prolonged evolutionary dynamics of MPNs and fitness advantage exerted by MPN-associated driver mutations in HSCs.Citation
Sousos N, Ní Leathlobhair M, Simoglou Karali C, Louka E, Bienz N, Royston D, et al. In utero origin of myelofibrosis presenting in adult monozygotic twins. Vol. 28, Nature Medicine. Springer Science and Business Media LLC; 2022. p. 1207–11.Journal
Nature MedicineDOI
10.1038/s41591-022-01793-4PubMed ID
35637336Additional Links
https://dx.doi.org/10.1038/s41591-022-01793-4Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1038/s41591-022-01793-4
Scopus Count
Collections
Related articles
- CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
- Authors: Kim SY, Im K, Park SN, Kwon J, Kim JA, Lee DS
- Issue date: 2015 May
- Characterization of CD34+ hematopoietic progenitor cells in JAK2V617F and CALR-mutated myeloproliferative neoplasms.
- Authors: Angona A, Alvarez-Larrán A, Bellosillo B, Longarón R, Camacho L, Fernández-Rodríguez MC, Pairet S, Besses C
- Issue date: 2016 Sep
- Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?
- Authors: Ahmed RZ, Rashid M, Ahmed N, Nadeem M, Shamsi TS
- Issue date: 2016
- Frequency of JAK2V617F, MPL and CALR driver mutations and associated clinical characteristics in a Norwegian patient cohort with myeloproliferative neoplasms.
- Authors: Lilleskare S, Vorland M, Vo AK, Aarsand AK, Reikvam H
- Issue date: 2023 Feb
- The different variant allele frequencies of type I/type II mutations and the distinct molecular landscapes in CALR-mutant essential thrombocythaemia and primary myelofibrosis.
- Authors: Pan Y, Wang X, Wen S, Liu X, Yang L, Luo J
- Issue date: 2022 Dec